PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues. (2023)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.eururo.2023.03.038
PubMed Identifier: 37087376
Publication URI: http://europepmc.org/abstract/MED/37087376
Type: Journal Article/Review
Volume: 84
Parent Publication: European urology
Issue: 3
ISSN: 0302-2838